Posted by Michael Wonder on 23 Aug 2022
FDA approves Abbott's new spinal cord stimulation device; provides tailored relief to multiple pain areas and adds more treatment options for evolving pain conditions
23 August 2022 - Abbott's new Proclaim Plus spinal cord stimulation system offers the next generation of stimulation therapy, giving physicians the ability to treat multi-site and evolving pain.
Abbott today announced that the US FDA has approved its new Proclaim Plus spinal cord stimulation system featuring FlexBurst360 therapy.
The next generation of Abbott's proprietary BurstDR stimulation, FlexBurst360 therapy offers pain coverage across up to six areas of the trunk and/or limbs and enables programming that can be adjusted as a person's therapeutic needs evolve.
